secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xeris Biopharma Holdings, Inc. (XERS)
CIK:        0001867096
Form:       8-K
Filed at:   2023-06-07T23:59:59+00:00
Accession:  0001867096-23-000089
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Xeris Biopharma stockholders elect three Class II directors and ratify E&Y as auditor at 2023 annual meeting
--------------------------------------------------------------------------------

- Dawn Halkuff elected with 53.2M for, 4.4M withhold, 31.2M broker non-votes.
- John Johnson elected with 42.9M for, 14.7M withhold, 31.2M broker non-votes.
- Jeffrey Sherman elected with 51.3M for, 6.3M withhold, 31.2M broker non-votes.
- Ratification of Ernst & Young as auditor approved: 87.8M for, 0.8M against, 0.2M abstain.
- No other matters were submitted to a vote at the meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867096/000186709623000089/0001867096-23-000089-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867096/000186709623000089/xers-20230607.htm
  HTML page:      https://secwatch.observer/filing/0001867096-23-000089

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer